Diabetics May Seek Compensation for Ketoacidosis Caused by Invokana

Diabetics who were hospitalized with ketoacidosis after taking Invokana may be entitled to compensation. A recent warning by the Food and Drug Administration (FDA) suggests that SGLT2 inhibitors cause a dangerous increase in the amount of acid carried in a patient’s blood, producing a life-threatening condition known as ketoacidosis.

→ Read More

Diabetics Seek Compensation for Heart Failure After Taking Onglyza

By a vote of 14-1, an advisory committee recommended that the Food and Drug Administration (FDA) mandate new warnings on drug labels for medications containing saxagliptin. Those medications, marketed as Onglyza and Kombiglyze XR, are prescribed to patients with type 2 diabetes as part of a plan to control blood sugar levels.

→ Read More